A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
about
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Therapeutic Targeting of TelomeraseTelomere and Telomerase Therapeutics in CancerMolecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Current status and perspectives of immune-based therapies for hepatocellular carcinomaVariations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancerCurrent Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for DiagnosisPotentiality of immunotherapy against hepatocellular carcinomaPeptide Vaccine: Progress and ChallengesImmunotherapeutic approaches for hepatocellular carcinomaValidation of glypican-3-specific scFv isolated from paired display/secretory yeast display library.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.Cause-specific telomere factors deregulation in hepatocellular carcinoma.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Therapeutic vaccines for gastrointestinal cancers.Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory studyTargeting telomerase-expressing cancer cells.The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production.Immune-based Therapy Clinical Trials in Hepatocellular CarcinomaHemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.Peptide vaccines for hepatocellular carcinoma.Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner.Clinical implications of basic research in hepatocellular carcinoma.Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies.Telomere and telomerase in chronic liver disease and hepatocarcinoma.Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.Developments in cancer vaccines for hepatocellular carcinoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.Targeting telomerase with radiolabeled inhibitors.Immunotherapy against cancer-related viruses.The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Immune-Mediated Therapies for Liver Cancer.Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.
P2860
Q26738293-D47F60E2-5EC1-4FAA-A152-EFDC6F581E54Q26741736-C626FB4E-B1CB-463B-9FFE-4CC51B0E3065Q26744808-9B6062BE-9023-4FBD-B4E2-A7DD0B9B9F3BQ26766689-6D46C5DC-B82D-4124-96B1-82DAEE87AE89Q26772326-4C7376DF-099C-4D70-8A6A-B0D6237A37E5Q26775381-9182C8D3-1232-40A1-B39F-4C17F8F686ABQ26781373-E8FE0219-2502-43E2-A99B-41F036ED8FA5Q26784228-E448EC96-AC04-402F-99A1-71F61AE3034BQ26851329-75EAA3A2-BAEC-4933-B4E0-48F460038F9DQ33779723-C24FD53B-1028-479A-8D4B-7E08DDB26C04Q34260503-A20ACA2D-2881-46C9-BB71-5FCF0F3A3168Q34548226-D2250D5F-1969-484B-9D3A-7939C89EE26CQ34982993-08E9754A-B592-49F9-87BE-CFAAF10D0D7CQ35567765-72D2735E-C8D8-4476-8ED8-2C64CB6B71E9Q35691248-EEDBA813-0074-4B87-9942-15BD9298D8EBQ35886589-8C73A8A5-9971-4DCD-9504-AFD3AF346FEAQ36017631-88D340A0-8871-4DF9-B30B-92D2593CAFEBQ36427736-7FE91536-AFD3-4381-B171-03729DCBAB6EQ36571270-F3CAD937-31FD-474C-8BB8-16E3E5E4DA52Q36644408-E7EEB9A6-5556-4C34-AC53-AB12E2BE8CB7Q36684407-27F0078D-1036-4C66-8AD4-F260A4BC0163Q36888010-1765A6D1-B068-4C46-864D-AB3387A7738DQ37057289-FC0A26E4-002E-4A8F-8C2D-C3470BACE812Q37289933-100F672F-4B9F-4915-B9F4-8E3813B210AAQ37514736-C9277387-07F0-43A0-89BB-0BEA7816114EQ37600523-B2CCEDDD-9458-49E2-A289-206805B5F5C5Q38161367-FE34B15B-C65E-40A5-8585-AEF92133BB30Q38177324-062B4F41-FB60-4D7D-8973-FA3352D75CA2Q38216014-E66073DC-ABFD-4356-9CC7-69E2F9E34D9CQ38231581-248A1B8A-7F5C-4EBB-B0CD-B3D49249B21AQ38533017-D44B7818-D913-4DF3-B1E8-D7FEC7B4DDF9Q38611895-78D219DC-4C53-4743-B311-932DAC40176DQ38625948-4CE88F53-0C6C-4C45-979A-93EB9AE60EB4Q38635474-00D2E04D-9610-4B06-A111-B08CD9023111Q38744397-2A3EAF9D-A8F0-48FA-A059-CB047187C0ACQ38778924-487C309A-E34C-45C9-8463-330EB6DFC880Q38835601-A4342EE6-C752-400D-8A15-D0B4A87C1DEBQ39144327-978DFE8D-6710-44C6-9F90-0349E0DA4CF6Q40160910-BE4879BE-E300-4155-BCE4-CDAF26304FBDQ42024872-2D1A4EF3-B81B-40C8-A27F-E2DB095002B7
P2860
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase II open label trial ev ...... anced hepatocellular carcinoma
@ast
A phase II open label trial ev ...... anced hepatocellular carcinoma
@en
A phase II open label trial ev ...... nced hepatocellular carcinoma.
@nl
type
label
A phase II open label trial ev ...... anced hepatocellular carcinoma
@ast
A phase II open label trial ev ...... anced hepatocellular carcinoma
@en
A phase II open label trial ev ...... nced hepatocellular carcinoma.
@nl
prefLabel
A phase II open label trial ev ...... anced hepatocellular carcinoma
@ast
A phase II open label trial ev ...... anced hepatocellular carcinoma
@en
A phase II open label trial ev ...... nced hepatocellular carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
A phase II open label trial ev ...... anced hepatocellular carcinoma
@en
P2093
Firouzeh Korangy
Gisele N'Kontchou
Lars A Ormandy
Michael P Manns
Michel Beaugrand
Nathalie Barget
Tim F Greten
P2860
P2888
P356
10.1186/1471-2407-10-209
P407
P577
2010-05-17T00:00:00Z
P5875
P6179
1052977430